Active Clinical Trials

April 19, 2023

Now Enrolling: ECOG-ACRIN Opens the ComboMATCH Patient Registration Trial as the Gateway to a Coordinated Set of Treatment Trials

ComboMATCH researchers are discovering new drug combinations that show promise for patients with advanced cancers, based on strong pre-clinical in vivo evidence of therapeutic effectiveness
April 19, 2023

Trial Spotlight: Kim Reiss on the EA2192/APOLLO Study for Certain Patients with Pancreatic Cancer

This phase 2 study is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
February 10, 2023

Now Enrolling: EA8212/BRIDGE for Non-Muscle Invasive Bladder Cancer

This phase 3 study is comparing the efficacy of intravesical chemotherapy after surgery to the usual approach of intravesical immunotherapy after surgery
February 10, 2023

TMIST Passes 80,000 Patients Enrolled

Even as screening mammography volumes remain below pre-pandemic levels, TMIST continues to enroll women at a strong pace
February 10, 2023

Trial Spotlight: A Closer Look at ECOG-ACRIN’s Myeloma Studies

These three trials are open and enrolling adults with multiple myeloma or at high risk of developing the disease
December 20, 2022

Re-Opened Trial: EA9152 for T-cell or B-cell Acute Lymphoblastic Leukemia

This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population
December 20, 2022

Trial Spotlight: Robert Ferris on the EA3132 Trial for Patients with Head and Neck Cancer

This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck
October 13, 2022

Trial Spotlight: Yishai Ofran on the EA9181 Study for Acute Lymphoblastic Leukemia

This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
August 16, 2022

NCI-MATCH precision medicine trial leads to FDA drug approval for BRAF V600E-mutated tumors

Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022

Trial Spotlight: Neha Vapiwala on the EA8191/INDICATE Study for Prostate Cancer

This phase III study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
June 21, 2022

Now Enrolling: EA9213 for T-Cell Acute Lymphoblastic Leukemia

This single-arm phase II study aims to rid patients of residual disease following initial treatment
June 21, 2022

Trial Spotlight Video: The EA8192 Study Team Discusses Their Trial for High Grade Upper Tract Urothelial Cancer

This study seeks to determine if neoadjuvant treatment with durvalumab and chemotherapy improves patient outcomes over chemotherapy alone